NCT04063852

Brief Summary

This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior treatment modalities who have elected to pursue PTNS therapy for LUTS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 27, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

August 19, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 21, 2019

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 27, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 27, 2022

Completed
Last Updated

February 14, 2023

Status Verified

February 1, 2023

Enrollment Period

3.8 years

First QC Date

August 19, 2019

Last Update Submit

February 13, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Urinary Frequency and/or Urinary Incontinence Episodes on 3 day voiding diary

    Change from baseline in the median number of urinary frequency and/or urinary incontinence episodes on a 3 day voiding diary at 3, 12, and 24 months

    up to 24 months.

Other Outcomes (6)

  • American Urological Association (AUA) Symptom Score

    up to 24 months

  • Michigan Incontinence Symptom Index

    up to 24 months

  • Neurogenic Bladder Symptom Score

    up to 24 months

  • +3 more other outcomes

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients presenting to the urology clinic at a tertiary care referral center.

You may qualify if:

  • Diagnosis of Multiple Sclerosis
  • Lower urinary tract symptoms (urinary frequency, urgency and/or incontinence)
  • Failed prior first and second line therapy (behavioral and pharmacotherapy)
  • Electing for Posterior Tibial Nerve Stimulation therapy for urinary symptoms
  • Patients performing Intermittent Catheterization are Eligible

You may not qualify if:

  • Indwelling catheters (urethral or suprapubic)
  • Currently pregnant or planning pregnancy
  • Unable to attend weekly office visits for PTNS
  • Urodynamic findings of bladder outlet obstruction
  • History of:
  • bladder reconstruction (augmentation cystoplasty, catheterizable channel) cystectomy bladder stones pacemaker or defibrillator malignancy of bladder sacral neuromodulation intravesical injection of onabotulinum toxin within 9 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Related Publications (1)

  • Lane GI, Mao-Draayer Y, Barboglio-Romo P, Clemens JQ, Gupta P, Dunn R, Qin Y, Cameron AP, Stoffel JT. A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods. BMC Urol. 2020 May 27;20(1):58. doi: 10.1186/s12894-020-00629-y.

MeSH Terms

Conditions

Multiple SclerosisLower Urinary Tract SymptomsUrinary Bladder, NeurogenicUrinary Bladder, OveractiveUrinary IncontinenceUrinary Incontinence, Urge

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeurologic ManifestationsUrinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrination Disorders

Study Officials

  • John Stoffel, MD

    University of Michigan

    PRINCIPAL INVESTIGATOR
  • Giulia Lane, MD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 19, 2019

First Posted

August 21, 2019

Study Start

February 27, 2019

Primary Completion

November 27, 2022

Study Completion

November 27, 2022

Last Updated

February 14, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations